Meritage Portfolio Management Acquires 10,622 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Meritage Portfolio Management raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,803 shares of the specialty pharmaceutical company's stock after acquiring an additional 10,622 shares during the quarter. Meritage Portfolio Management owned approximately 0.11% of Supernus Pharmaceuticals worth $1,926,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $25,000. Financial Management Professionals Inc. purchased a new position in shares of Supernus Pharmaceuticals in the 1st quarter worth approximately $30,000. Versant Capital Management Inc raised its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after acquiring an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $42,000. Finally, Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 870 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, June 21st.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $32.00 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.66 and a fifty-two week high of $40.28. The company has a market cap of $1.79 billion, a PE ratio of 28.82 and a beta of 0.70. The business has a 50-day simple moving average of $32.26 and a two-hundred day simple moving average of $33.89.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.